Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
NCT07828756Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07828756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828756.